<DOC>
	<DOCNO>NCT00550628</DOCNO>
	<brief_summary>RATIONALE : Diagnostic imaging procedure , fludeoxyglucose F 18 PET , may effective detect cancer recurrence cancer , premalignant polyp . PURPOSE : This clinical trial study fludeoxyglucose F 18-PET imaging see well work determine protein gene expression signatures patient premalignant polyp colon cancer .</brief_summary>
	<brief_title>Fludeoxyglucose F 18 PET Imaging Determining Protein Gene Expression Signatures Patients With Premalignant Polyps Colon Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine feasibility ex-vivo imaging colon cancer colon polyp use fludeoxyglucose F 18 positron emission tomography ( FDG PET ) . - To evaluate difference molecular genetic profile FDG-positive polyp FDG-negative polyp suggest gene mutation abnormal mRNA and/or protein expression may require FDG avidity ( `` signature '' FDG avidity ) . Secondary - To evaluate difference molecular genetic profile FDG-positive polyp FDG-positive cancer suggest gene mutation abnormal mRNA and/or protein expression may require cancer formation ( `` signature '' cancer ) . - To evaluate difference molecular genetic profile normal colonic mucosa , polyp , cancer . - To evaluate difference similarity molecular genetic profile FDG-positive cancer polyp . OUTLINE : Part I : Patients receive fludeoxyglucose F 18 ( FDG ) IV follow 45-60 minute later surgery remove part colon . Tissue sample colon undergo positron emission tomography ( PET ) imaging . Part II : Tissue sample analyze glucose transporter protein ( Glut-1 , 2 , 3 , 4 , 5 , 7 ) via IHC ; presence K-ras mutation ( invariable mutant site codon 12 , 13 ) via PCR ; 18q deletion via fluorescence situ hybridization ( FISH ) DCC IHC ; MCT-1 , Hex-1 , Hex-2 , COX-2 expression level via quantitative RT-PCR method western blot ; APC mutation via PCR- In Vitro Synthesized-Protein Assay RT-PCR direct sequencing method ; p53 mutation detection via immunochemistry , RT-PCR direct sequence method , western blot ; methylation alteration MGMT , CDKN2A , HLTF , MLH1 , TIMP3 , HIF1 , BNIP3 , HRK via methylation detect microchip ; specific gene methylations via methylation-specific PCR . Some tissue sample may save banked future study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>Subject Patients eligible entry study : Age 15 100 Undergoing resection nonsarcomatous primary colon neoplasm also 2 adenoma great equal 710mm size anticipate remove colon specimen . It known MSKCC outside study ( barium enema , endoscopy , PET/CT , CT colonography ) patient least 2 proven adenomas 710 mm great primary colon neoplasm Subject Insulindependent diabetic ( establish routine history presurgical laboratory test ) .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>neoplasm uncertain malignant potential</keyword>
	<keyword>colon cancer</keyword>
</DOC>